Moreover, a CTLA-4 inhibitor has also been approved for the treatment of NSCLC, and the combination therapy with PD-1 inhibitors has resulted in a relatively high response rate and prolonged overall survival time [17, 24–26]. Here, CTLA4 is linked to non-small cell lung carcinoma.